Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.
Lucid Diagnostics Inc. reports developments in commercial-stage cancer prevention diagnostics for patients with gastroesophageal reflux disease who are at risk for esophageal precancer and esophageal adenocarcinoma. The company, a subsidiary of PAVmed Inc., markets the EsoGuard Esophageal DNA Test and uses the EsoCheck Esophageal Cell Collection Device to collect samples through a brief, noninvasive office procedure.
Recurring updates cover EsoGuard commercialization, healthcare-system access, clinical evidence for esophageal precancer detection, quarterly business results, cash resources, and conference presentations. Lucid news also includes capital actions such as registered common stock offerings and related use of proceeds for working capital and general corporate purposes.
PAVmed (NASDAQ:PAVM) reported Q1 2026 results and a business update spanning Lucid Diagnostics (NASDAQ:LUCD) and Veris Health. Revenue was $22 thousand, operating expenses $8.1 million, and GAAP net loss attributable to common stockholders about $7.0 million or $(4.42) per share. Non-GAAP adjusted net loss was $1.9 million or $(1.17) per share. Cash and equivalents rose to $6.5 million from $1.5 million at year-end. Lucid recognized $1.3 million in EsoGuard revenue on 3,177 tests and raised roughly $17 million, ending with $45 million pro forma cash and runway into 2027. Veris advanced its implantable physiological monitor toward a planned FDA 510(k) submission and expanded its commercial engagement with OSU-The James.
Lucid Diagnostics (Nasdaq: LUCD) reported first quarter 2026 results and a business update. The company processed 3,177 EsoGuard tests and generated $1.256 million in revenue, with operating expenses of $13.4 million and GAAP net loss of $13.9 million, or $(0.17) per share.
Non-GAAP adjusted loss was $10.5 million. An underwritten equity offering added about $17 million, supporting $45 million in proforma cash and runway into 2027. Management highlighted efforts toward Medicare coverage, expanded payer and health system engagement, and a strong presence at DDW with EsoGuard clinical data and guideline visibility.
PAVmed (Nasdaq: LUCD) will host a First Quarter 2026 business update conference call and webcast on May 15, 2026 at 8:30 AM ET. CEO Lishan Aklog will provide a business update and CFO Dennis McGrath will discuss Q1 2026 financial results.
Investors can join via webcast at the investor relations page on pavmed.com or by telephone (U.S. 1-800-836-8184; international 1-646-357-8785). A replay will be available on pavmed.com for 30 days after the call.
Lucid Diagnostics (Nasdaq: LUCD) will host a business update conference call and webcast on Thursday, May 14, 2026 at 8:30 AM ET. CEO Lishan Aklog will provide a business update and CFO Dennis McGrath will discuss first quarter 2026 financial results.
The live webcast and a 30-day replay will be available on the company's investor relations website at luciddx.com. Telephone access is available for U.S. and international listeners with provided dial-in numbers; attendees should reference the conference call name "Lucid Diagnostics Business Update."
Lucid Diagnostics (NASDAQ: LUCD) closed an underwritten registered direct offering of 18,000,000 common shares at $1.00 per share, generating approximately $18 million in gross proceeds on April 24, 2026.
The offering was anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder. Net proceeds are intended for working capital and general corporate purposes.
Lucid Diagnostics (Nasdaq: LUCD) priced an underwritten registered direct offering of 18,000,000 common shares at $1.00 per share, anchored by a $15 million institutional investment, with gross proceeds of approximately $18 million. The company intends to use net proceeds for working capital and general corporate purposes.
The offering is expected to close on or about April 24, 2026, subject to customary conditions. Canaccord Genuity and BTIG are joint bookrunners. The offering is made under a Form S-3 shelf registration declared effective March 26, 2026.
Lucid Diagnostics (Nasdaq: LUCD) announced that CEO and chairman Lishan Aklog, M.D., will take part in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 10:15 AM EDT.
The event will be webcast live and a replay will be archived on the company's Investor Relations website for 30 days.
PAVmed (LUCD) appointed Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices, and relaunched its medical device portfolio on April 2, 2026. The company formed a new subsidiary, Octeris, and executed a definitive license with Duke University for multi-modality endoscopic esophageal imaging.
The portfolio includes the PortIO implantable intraosseous vascular access device and the Duke-licensed endoscopic imaging technology; Virgilio will also lead subsidiaries PortIO Inc. and Octeris Inc.
PAVmed (NASDAQ: PAVM) reported Q4 and full-year 2025 results and a business update on March 30, 2026. Highlights include a $30M Series D preferred offering, a $15M senior secured note, elimination of outstanding convertible securities, relaunch of medical devices, Veris commercialization with OSU-The James, and Lucid Diagnostics progress on EsoGuard.
Financials: Q4 GAAP net loss attributable to common stockholders was $(1.8M) and non-GAAP adjusted loss was $(0.9M); cash and equivalents were $1.5M as of December 31, 2025.
Lucid Diagnostics (Nasdaq: LUCD) reported 4Q25 EsoGuard revenue of $1.5M from 3,664 tests and full-year revenue of $4.706M. The company secured a national VA contract covering ~170 VA medical centers with Medicare-aligned pricing of $1,938 and reported positive real-world data showing 95% technical success and 95% of procedures under two minutes. Cash and equivalents were $34.7M at year-end. GAAP net loss was $16.3M for 4Q25 (EPS $(0.12)) and non-GAAP adjusted loss was $12.6M.